Real-time live tissue sensitivity assay for pancreatic adenocarcinoma
A new research paper titled "Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma" has been published in Oncotarget.
Sep 19, 2023
0
12
A new research paper titled "Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma" has been published in Oncotarget.
Sep 19, 2023
0
12
A new study has shed light on why immunotherapy does not always work in certain types of cancer. Led by researchers at EMBL's European Bioinformatics Institute (EMBL-EBI), Cold Spring Harbor Laboratory (CSHL), and the Massachusetts ...
Sep 14, 2023
0
25
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to osimertinib alone, according to research presented at the International Association ...
Sep 11, 2023
0
7
The Taiwan National Lung Cancer Early Detection Program detected 85% of lung cancer cases at either a phase 0 or phase 1 level, demonstrating that lung cancer screening can detect lung cancer at an early enough phase to allow ...
Sep 11, 2023
0
2
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1
The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according ...
Sep 9, 2023
0
18
In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time for breast cancer patients.
Sep 8, 2023
0
63
Results of a multicenter phase II clinical trial led by the University of Chicago Medicine Comprehensive Cancer Center show that adding an immunomodulatory agent to treatment with the targeted tyrosine kinase inhibitor (TKI) ...
Sep 1, 2023
0
0
Fresh discoveries about a certain type of immune cell could give lung cancer patients a more accurate prognosis and better identify who will benefit from immunotherapies.
Aug 30, 2023
0
11